Journal article

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer

Wilfried EE Eberhardt, Paul Mitchell, Joan H Schiller, Michael P Brown, Michael Thomas, Glenn Mills, Valentine Jehl, Shweta R Urva, Jeffrey J De Leo, Sven Gogov, Vassiliki Papadimitrakopoulou

INVESTIGATIONAL NEW DRUGS | SPRINGER | Published : 2014

Abstract

INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin ± bevacizumab. This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin ± bevacizumab for advanced NSCLC. METHODS: Adults with advanced NSCLC naive to systemic therapy were enrolled. A Bayesian dose-escalation model was used to identify feasible daily or weekly everolimus doses given with paclitaxel (200 mg/m(2) q21 days) and carboplatin (AUC 6 mg/mL/min q21 days) (step 1) and paclitaxel (200 mg/m(2) q21 days), carboplatin (AUC 6 mg/mL/min q21 days), and bevacizumab (15 mg/kg q21 days) (step 2). Primary endpoint was end-of-cycle 1 ..

View full abstract

University of Melbourne Researchers